Welcome to our dedicated page for Precipio news (Ticker: PRPO), a resource for investors and traders seeking the latest updates and insights on Precipio stock.
Precipio, Inc. reports developments from its specialty cancer diagnostics business, which focuses on diagnostic products and services for cancer, including hematologic malignancies. Company updates commonly address performance in the Pathology Services Division and Products Division, customer and laboratory workflow trends, shareholder update calls, and balance sheet actions tied to debt, warrants, and common-stock financing arrangements.
Precipio news also covers its proprietary diagnostic technologies, including the Bloodhound BCR::ABL1 assay for Chronic Myeloid Leukemia, study publications, scientific meeting presentations, and collaborations involving clinical laboratories and cancer centers. Operational disclosures may include cybersecurity response, service continuity, and the company’s use of laboratory-developed technologies that are validated clinically and commercialized for the broader laboratory market.
Precipio, Inc. (NASDAQ: PRPO) will host its Quarter 1-2020 corporate update call on May 19, 2020, at 5:00 PM ET. Callers can join by dialing 844-695-5519 or internationally at 1-412-902-6760. Registration is available at here, allowing participants to bypass the operator. Precipio aims to improve diagnostic accuracy through collaborations with leading academic institutions, including Yale and Dana-Farber. The call will address questions submitted via email to investors@precipiodx.com. A replay will be accessible 24 hours post-call on the company's investor page.